The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up.
C F Winkler; E A Sausville; D C Ihde; A B Fischmann; G P Schechter; P P Kumar; J R Nibhanupdi; J D Minna; R W Makuch; J L Eddy (Profiled Author: Edward A Sausville)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(7):1094-100.Abstract
Thirty-nine patients with cutaneous T cell lymphoma (CTCL; including mycosis fungoides or the Sezary syndrome) with no previous treatment other than topical therapy or oral corticosteroids, received total skin electron beam irradiation (TSEB) and either sequential or simultaneous systemic chemotherapy. Median follow-up, measured from the time of initiation of therapy to the time of analysis, is in excess of 6 years and extends to 100+ months. Thirteen patients with stage I disease (limited to skin with no adenopathy) received 3,000 rad total skin electron beam irradiation followed by three 2-week courses of daily intravenous (IV) mechlorethamine. Twenty-six patients with advanced disease (stage II-IV) received 2,400 rad of TSEB and simultaneous chemotherapy with two alternating three-drug regimens: vinblastine, doxorubicin, and bleomycin (VAB) alternating with cyclophosphamide, methotrexate, and prednisone (CMP) administered over 54 weeks. The overall response rate was 92% with 16 of 39 patients (41%) achieving a histologically documented complete response (CR). Stage I patients had a significantly increased CR rate (77%) compared with stage II-IV (P less than .01). The overall 6-year survival was 92% for stage I patients and 26% for stage II-IV patients (23%) (P less than .001). Among ten completely responding stage I patients, six remain alive and disease-free in excess of 72 months. The median disease-free survival is 26 months for completely responding stage II-IV patients (P = .04), but none are continuous disease-free survivors after protocol treatment. We conclude that combined modality treatment can be safely administered and produces prolonged disease-free survival in some stage I patients, but not in more advanced stage patients.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
E Dmitrovsky; M J Matthews; P A Bunn; G P Schechter; R W Makuch; C F Winkler; J Eddy; E A Sausville; D C IhdeJournal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(2):208-15.
G Lange Wantzin; W C Saxinger; A Woods; J K Larsen; K Thomsen; R C GalloActa dermato-venereologica 1984;64(5):395-9.
B J Poiesz; F W Ruscetti; J W Mier; A M Woods; R C GalloProceedings of the National Academy of Sciences of the United States of America 1980;77(11):6815-9.
Appears in this Publication
Author of this Publication